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Human C4b-binding protein (C4BP) functions as a cofactor to factor I in the degradation of C4b and accelerates the decay rate of the C4b2a 
complex. In this study we describe a monoclonal antibody directed against he cc-chain of C4BP that inhibits the binding of C4b to C4BP. In order 
to identify the structural domain of the cc-chain of C4BP that interacts with C4b. tryptic fragments of C4BP were generated. Amino acid sequence 
analysis of the fragments revealed that the residues Se?“‘-Arg js6 of the a-chain of C4BP contain the epitope of this antibody, and as a consequence, 
that this part of the a-chain of C4BP is likely to be involved in the interaction with C4b. 
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1. INTRODUCTION 
C4b-binding protein (C4BP) primarily functions as a 
cofactor to factor I in the degradation of C4b, but in 
addition accelerates the decay rate of the C4b2a com- 
plex and interacts with the vitamin K-dependent protein 
S [ 1,2]. Recently, it has been reported that C4BP can 
bind to serum amyloid P, but the importance of this 
latter interaction remains to be determined [3]. The 
major form of C4BP is composed of 7 identical a-chains 
(70 kDa) and a single B-chain (45 kDa) that are linked 
by disulfides [4-61. Each of the a-chains consists of 549 
amino acids and forms a tentacle with the N-terminus 
located at the periphery of the tentacle, whereas the 
C-termini are located in a central core [5,7]. The binding 
sites for C4b were located on the peripheral half of each 
tentacle [8,9], whereas one single binding site for protein 
S was localized on the B-chain [lo-121. The P-chain 
consists of 235 amino acids and the 175 N-terminal 
residues can be divided into 3 short consensus repeats 
(SCRs) homologous to the 8 SCRs in the a-chain of 
C4BP [11,13-151. 
and the activated C4b (181 kDa). The cleavage of C4b 
by factor I and C4BP in the a’-chain of C4b leads to the 
generation of the C4c and C4d fragments [20]. The N- 
terminal end of the ol’-chain of C4b between Ala738 and 
Arg826 is involved in C4BP binding [21,22]. 
Complement C4 (189 kDa) is a glycoprotein consist- 
ing of 3 disulfide-linked a (88 kDa), /? (72 kDa) and r 
(32 kDa) chains [l&19]. The proteolytic cleavage by 
Cls in the N-terminal part of the a-chain of C4 leads 
to the generation of the activation peptide C4a (8 kDa) 
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Limited proteolysis of C4BP by chymotrypsin results 
in cleavage of the a-chain, at Tyr3g5 and Trp425, yielding 
a 48 kDa fragment, constituting the major part of the 
a-chain, and a 160 kDa fragment representing the cen- 
tral core of C4BP [5,23]. Proteolysis of C4BP with tryp- 
sin results in cleavage in the middle of each a-chain of 
C4BP thereby generating fragments of 3648 kDa. The 
tryptic fragments remain disulphide-linked, in contrast 
to the chymotrypsin digestion [24]. The C4b-binding 
and factor I cofactor activity are located in the chymo- 
tryptic 48 kDa fragments [23] and the region for C4b 
binding was tentatively assigned to residues 332-395 of 
the a-chain of C4BP [25]. However, as no direct C4b- 
C4BP binding studies could be performed the residues 
actually important for C4b binding remained to be iden- 
tified. The positioning of the C4b binding site to the 
C-terminal half of the a-chain seemed not to be compat- 
ible with the results obtained from electron microscopic 
imagery of C4BP-C4b complexes [5], although it is pos- 
sible that the N-termini of the a-chains of C4BP fold 
inwards towards the core leaving the putative cofactor 
sites at the extremities of the molecule. Anti-C4BP-spe- 
cific mAbs have been described that were found to react 
with the 48 kDa chymotryptic fragment of the a-chain 
of C4BP and abolished C4b binding [9,26]. However, 
the C4b-binding site on C4BP could not be identified by 
these mAb in detail, because these apparent discontinu- 
ous epitopes were not available on reduced C4BP. In the 
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present study, we have obtained a mAb that reacted 
with the reduced a-chain of C4BP and inhibited the 
binding of C4BP to C4b that enabled us to identify a 
region of the a-chain of C4BP that is involved in the 
binding of C4b. 
2. EXPERIMENTAL 
2.1. Proteins 
Human C4BP and C4b were purified as described [12,27]. Protein 
concentrations were determined by measuring the absorbance at 280 
nm using an extinction coefficient (18, 1 cm) of 14.3, 14.1 and 8.7 for 
IgG, C4BP and C4, respectively [28]. C4BP was radiolabeled with 
Na12’I (Amersham, Buckinghamshire, UK) using Iodobeads (Pierce 
Chemical Co.) [26]. 
2.2. mAbs 
MAbs specific for C4BP were obtained as described [26] using either 
C4BP or its central core as the antigen. Hybridoma supernatants were 
screened for the presence of mAbs by an ELISA in which reduced 
C4BP was used as the antigen. Positive clones were subcloned by 
limiting dilution, expanded, and antibody-rich ascites fluid was ob- 
tained [26]. Murine IgGs were isolated by protein G-Sepharose 4FF 
(Pharmacia LKB Biotechnology Inc., Uppsala, Sweden). 
2.3. Electrophoretic and immunochemical techniques 
SDS-PAGE was performed according to Laemmli [29], and the gels 
were either stained with Coomassie brilliant blue R-250 or im- 
munoblotted [30]. The Immobilon-P membranes (Millipore, Mol- 
sheim, France) were either blocked with 5% (w/v) non-fat dry milk in 
50 mM Tris-HCl, pH 7.4, 150 mM NaCl, incubated with anti-C4BP 
mAb and visualized with peroxidase-conjugated rabbit anti-mouse 
IgG (Dako, Glostrup, Denmark), or stained with Coomassie brilliant 
blue. Prestained molecular weight markers were from Bio-Rad Labs. 
(Richmond, CA, USA). 
2.4. C46-C4BP binding assay 
Direct binding of C4BP to C4b was measured as described [26]. 
Briefly, microtiter plates (Dynatech remova strips, Plockingen, FRG) 
were coated with C%b, radiolabeled C4BP was applied and the plates 
were incubated overnight at 4°C. The wells were washed and the 
amount of C4BP bound to C4b was measured. The various antiC4BP 
mAbs were added together with the radiolabeled C4BP to examine 
their effect on the binding of CXBP to C4b. 
2.5. Competition between different mAbs for C4BP 
Microtiter plates were coated with each mAb, washed and blocked 
as described [26]. The various mAbs (35 &ml final concentration) 
were added to parallel mixtures of non-labeled (1 &ml final concen- 
tration) and radiolabeled C4BP, transferred to the wells and incubated 
overnight at 4°C. The wells were washed and the amount of bound 
C4BP was measured. 
2.6. Peptide mapping by SDS-PAGE and immunoblotting 
C4BP (1 mg/ml) was incubated with 3% (w/w) TPCK-trypsin 
(Worthington Biochemical Corporation, NJ) at 37°C for 2 h. The 
digestion was terminated by incubating the samples for 5 min at 90°C 
with 5% (v/v) 2-mercaptoethanol, 10 mM Tris-HCI, 2% SDS, 0.01% 
(w/v) Bromophenol blue, 10% (v/v) glycerol, pH 6.8. The digest was 
separated by SDS-PAGE under reduced conditions and subsequently 
transferred to an Immobilon membrane. The membranes were incu- 
bated with the antiC4BP mAbs and parallel stained with Coomassie 
brilliant blue. The fragments detected by Coomassie brilliant blue 
staining were excised and their N-terminal amino acid sequencees were 
determined with an Applied Biosystems model 477A gas-phase se- 
quencer, connected to an on-line 120A PTH Analyzer [31]. 
3. RESULTS 
3.1. Production of mAbs against C4BP 
Previously, we reported on the preparation and char- 
acterization of mAbs against C4BP that were prepared 
by immunizing mice with either C4BP or the 160 kDa 
chymotryptic central core [26]. In the present study, we 
rescreened the remaining antiC4BP positive clones for 
reactivity with reduced C4BP. Using this strategy 7 new 
clones which reacted with reduced C4BP were obtained 
and characterized for their effect on the binding of 
C4BP to C4b. One rnAb, designated C4BP-7F2, was 
selected and characterized in detail. 
To determine whether the mAbs were directed 
against similar or different epitopes, competition exper- 
iments were performed. For this, the various mAbs were 
mixed with [“‘I]C4BP and added to microtiter wells 
containing the immobilized mAbs C4BP-3B9 and 7B4, 
that previously were found to inhibit C4b binding [26]. 
From the data obtained (not shown) the antiC4BP 
mAbs C4BP-3B9 and 7B4, resulted in strong inhibition 
of [‘251]C4BP binding to the mAb C4BP-7F2, suggesting 
that the epitopes of the mAbs C4BP-3B9, 7B4 and 7F2 
are in proximity. 
3.2. Immunoblotting analysis of C4BP 
To examine the reactivity of the anti-C4BP mAbs 
with the disulfide-linked a- and p-chains, C4BP was 
reduced and analyzed by SDS-PAGE and immunoblot- 
ting. Table I shows the immunoblotting characteristics 
of the anti-C4BP mAbs and together with the competi- 
tion experiments, the mAbs can roughly be subdivided 
into 3 groups: group A, C4BP-2E9 and 7F2; group B, 
C4BP-5Cll and 6Bl; and group C, C4BP-3F9, 6Bll 
and 9F6. All mAbs from groups A-C were shown to 
react with the reduced a-chain, but remarkably, the 
mAbs from group B in addition seemed to react with the 
B-chain. This may suggest that the mAbs from group B 
recognize a common epitope that could be present on 
Table I 
Immuno-blotting analysis of C4BP 
Group 
A 
B 
C 
mAb 
2E9 
7F2 
5Cll 
6Bl 
3F9 
6Bll 
9F6 
Reduced chains 
a B 
++ - 
++ - 
+ + 
+ + 
+ - 
+ 
+ - 
The different mAbs were immobilized in microtiter wells and the 
binding of [“‘I]C4BP was measured. The influence of the different 
mAbs on C4BP binding to each solid-phase mAb was examined by 
adding the various mAbs to the [“‘I]C4BP. - indicates no, + indicates 
weak and ++ indicates strong staining with the mAb. 
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the SCRs of both the a- and B-chains as the sequence 
homology between the 3 SCRs of the B-chain and the 
8 SCRs of the a-chain has been found to be between 17 
and 35% [l 11. 
3.3. The effect of mAbs on the C4BP binding to C4b 
The same mAbs were examined for their effect on the 
binding of C4BP to C4b. For this purpose C4b was 
coated on microtiter plates and incubated with 
[“‘I]C4BP in the presence of an excess of anti-C4BP 
mAb. Table II demonstrates that the mAb C4BP-7F2 
(group A) inhibits the binding of [‘*‘I]C4BP to C4b 
almost completely, whereas the other mAbs showed no 
or minor effect. Some significant inhibition was also 
observed by the presence of mAb C4BP-9F6. 
3.4. C4b-binding site on C4BP 
Our strategy for determining the structural domain(s) 
of C4BP that bind C4b involved a tryptic fragmentation 
of the molecule. SDS-PAGE of the reduced tryptic frag- 
ments of C4BP showed the liberation of 5 fragments 
derived from the a-chain of C4BP with apparent M,‘s 
of about 48 kDa (Tl), 45 kDa (T2), 36 kDa (T3), 32 
kDa (T4) and 30 kDa (T5) (Fig. 1A). As the P-chain 
hardly stains with Coomassie brilliant blue [6], its pres- 
ence was not detected. Immunoblotting analysis of the 
tryptic cleavage products of C4BP with the mAb C4BP- 
7F2 (Fig. IB) revealed that this mAb reacts strongly 
with T3, and in addition recognized T4 and T5. To 
locate the tryptic fragments containing a possible C4b 
binding fragment within the structure of the C4BP mol- 
ecule, the N-terminal sequences of the excised bands 
A 
C4BP-a! - 
Tl- 
2- 
3 
4-- 
5- 
Table II 
Effect of the mAbs on the complex formation of C4BP with C4b 
Group mAb Inhibition of binding to C4BP for 
C4b* 
A 2E9 20 
IF2 87 
B 5Cll 0 
6Bl 0 
C 3F9 30 
6Bll 0 
9F6 54 
*The percentage of inhibition of C4BP binding to solid-phase C4b was 
determined with radiolabeled C4BP in the presence of an excess of the 
different antiC4BP mAbs, as described in section 2. The percentage 
of inhibition is expressed as % of the binding of C4BP alone. The data 
represent he average of 3 determinations. 
were determined. The N-terminal sequence obtained for 
T3 matched the sequence derived from the cDNA stud- 
ies [13,14,32] and indicated that T3 started at residue 
Ser333. The observation that the generation of the tryptic 
fragment T3 is due to cleavage by trypsin at Lys332 is in 
agreement with an apparent similar tryptic T3 fragment 
obtained by limited proteolysis studies of C4BP by 
Chung and Reid [25]. The N-terminal sequences ob- 
tained for the tryptic fragments, T4 and T5, both started 
at position His13*. On the basis that there are only 2 Arg 
residues present (positions 356 and 370) in the fragment 
between Ser333 and Tyr39s (the latter representing the 
cleavage site for chymotrypsin for the generation of the 
48 kDa tentacles of C4BP), where trypsin has been 
106 
80 
50 
33 
28 
18 
Fig. 1. SDS-PAGE and immunoblotting analysis of proteolytic fragments of C4BP. C4BP was digested with trypsin as described in section 2 and 
subsequently applied on 12.5% SDS-PAGE under reduced conditions. The gels with intact C4BP (a-chain) and the tryptic digest stained with 
Coomassie brilliant blue are shown to the left (A), and to the right (B) are the same polypeptides transferred to Immobilon membranes, which 
were analyzed with the mAb C4BP-7F2 (5 pg/ml). 
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found to perform enzymatic cleavage of the molecule 
[ 131, and since the apparent M, of the T4 and T5 frag- 
ments are about 32 and 30 kDa respectively, it is reason- 
able to conclude that the domain of the a-chain of CQBP 
recognized by the inhibitory mAb C4BP-7F2 is identical 
to the domain of SCR 6 of the a-chain of C4BP, Ser333 
through Arg 356 Additional support for this comes from . 
a previous study [13] where a large population of suc- 
cinylated, tryptic peptides of the a-chain of C4BP, that 
had been obtained after extensive trypsin cleavage, had 
been analyzed for their N-terminal sequences. They 
identified the fragments ST3-3 and ST9-9 starting at 
Thr371 and Phe357 respectively, thus suggesting that the 
T4 and T5 fragments are apparently generated by the 
same cleavages. The localization of the tryptic frag- 
ments and their overlapping region corresponding with 
the epitope of mAb C4BP-7F2 is demonstrated in Fig. 
2. As a consequence of the above observations that the 
mAb C4BP-7F2 has been found to inhibit the interac- 
tion of C4b with C4BP, the residues Ser333-Arg356 of the 
cc-chain of C4BP are likely to be part of the putative 
C4b-binding site. 
T T T 1 CT CT s’ 
t-t V I 
N- 1 2 3 4 5 6 7 8 
I 
s\ 
T3 
4 + 
T4 - 
T5 - 
I 
Fig. 2. Localization of the tryptic fragments containing the epitope of 
mAb C4BP-7F2 in a model of C4BP. (Upper part) The 7 a-chains and 
the distinct B-chain of C4BP (hatched bar) are disulfide linked to each 
other near their C-termini. The intercham disulfide bridges are tenta- 
tively placed between the non-homologous cysteins. (Lower part) One 
of the u-chains showing the 8 SCRs (denoted l-8). The tryptic (T) and 
chymotryptic cleavage sites (CT) are indicated by the arrows. The 
proposed position for the epitope of the mAb C4BP-7F2 (Ser”‘- 
Arg356), and as a consequence the putative C4b-binding site, is indi- 
cated. 
4. DISCUSSION 
Human C4BP contains multiple binding sites for C4b 
that are localized on the chymotryptic 48 kDa frag- 
ments of the cc-chain [23]. Fujita et al. [9] reported for 
the first time the preparation of anti-C4BP specific 
mAbs. One of these mAbs (TK 3) reacted with the 48 
kDa chymotryptic fragments of the a-chain of C4BP 
and inhibited the binding of C4b. More recently, we 
have described anti-C4BP specific mAbs (C4BP-3B9, 
7B4,8Cll, 9H3,9HlO) with apparent similar character- 
istics [26] that also abolished C4b binding to C4BP. 
However, the C4b-binding site on C4BP could not be 
identified by these mAbs in more detail, because their 
discontinuous epitopes were not available on the re- 
duced molecule. 
In this study an anti-C4BP-specific mAb, designated 
C4BP-7F2, directed against the reduced a-chain of 
C4BP, was obtained that inhibited the binding of C4b 
to C4BP. Tryptic proteolysis of C4BP and amino acid 
sequence analysis revealed that the residues Ser333- 
Arg356 of the a-chain of C4BP contain the epitope of this 
mAb. As a consequence this part of the a-chain of C4BP 
is likely to be involved in the interaction with C4b. This 
result supports previous work [25] with the tentative 
placement of a putative C4b-binding site to residues 
332-395 of the 6th SCR of the a-chain of C4BP. How- 
ever, the C4bC4BP inhibition experiments of this 
study and others [9,26] with 2 populations of mAbs with 
continuous and discontinuous epitopes, suggest that 
both the tertiairy structure of the a-chain of C4BP and 
at least the linear sequence Ser333-Arg356 areimportant 
for a proper interaction of C4BP with C4b. Our exper- 
iments do not rule out the possibility that other sites 
(conformational or structural) in the a-chain of C4BP 
are also important for its interaction with C4b. One or 
more epitopes towards the N-terminus of the a-chain of 
C4BP might be required to support or facilitate the 
non-covalent binding with C4b. This latter may be in 
agreement with the electron microscopic studies [5] or 
with a previous suggestion that a region with an identi- 
cal amino acid sequence (VTYSCDP) found in both the 
third SCR of C4BP and the membrane cofactor protein 
may be involved in C4b binding [26,33]. 
In conclusion, the present observations allow a tenta- 
tive assignment of the C4b-binding site to the residues 
Ser333-Arg356 of the 549 amino acid long a-chain of 
C4BP (Fig. 2) but a possible involvement of other parts 
of the molecule can not be excluded. 
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